[1] Cong W M, Bu H, Chen J, et al. Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol, 2016, 22:9279-9287.
[2] 朱健, 曹治平, 唐芳芳. MSCT三期增强扫描对小肝癌的临床诊断价值. 海南医学, 2017, 28:257-259.
[3] Liu H, Xu Y, Xiang J, et al. Targeting Alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer. Clin Cancer Res, 2017, 23:478-488.
[4] Roli L, Pecoraro V, Trenti T. Can NGAL be employed as prognostic and diagnostic biomarker in human cancers? A systematic review of current evidence. Int J Biol Markers, 2017, 32:e53-e61.
[5] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 21:865-872.
[6] 李强, 赖少侣, 张卫,等. MSCT肝包膜侵犯征象对肝癌微血管侵犯诊断价值研究. 临床放射学杂志, 2017:838-840.
[7] 姚承, 王琰. 320层MSCT对肝癌患者肝外供血动脉的诊断效果. 医疗卫生装备, 2016, 37:84-86.
[8] 王楚铭. 多排螺旋CT肝血流灌注参数诊断原发性肝癌的意义探讨. 实用肝脏病杂志, 2016, 19:223-224.
[9] 徐恩君, 陈秋莉, 李涛, 等. 血清 AFP、AFP-L3联合检测在原发性肝癌中的诊断价值. 安徽医科大学学报, 2016, 51:1066-1070.
[10] 陆兴热, 骆葱, 陈凤羽,等. AFP、GP73、SOD联合检测在原发性肝癌患者诊断中应用价值. 中国普通外科杂志, 2016, 25:1076-1080.
[11] Marchewka Z, Tacik A, Piwowar A. KIM-1 and NGAL as potential biomarkers for the diagnosis and cancer progression. Postepy Hig Med Dosw, 2015, 70:329-336.
[12] 唐成佳, 余天雾. NGAL 及 MMP9在原发性肝癌患者血清中表达及意义. 重庆医学, 2016, 45:2357-2359. |
